Lexaria Bioscience Corp. (CSE:LXX, OTCQX:LXRP), (the “Company” or “Lexaria”) an innovator in drug delivery platforms, reports on its existing technology licensees that have signed definitive contracts to use Lexaria’s revolutionary DehydraTECHTM absorption technology within their existing and emerging brands.

“The first half of 2019 delivered a period of unprecedented achievements for Lexaria,” said Chris Bunka, Chief Executive Officer. “We signed more license agreements than ever before in our Company’s history, many of which were larger in scope than anything previous. We also launched our brand-new business division Lexaria Nicotine which is disrupting nicotine delivery methods that already attracted one of the world’s largest nicotine companies, which has licensed our technology.”

Year to date 2019, Lexaria has announced:

  • 1 new license agreement with *Altria Ventures Inc, an indirect wholly-owned subsidiary of Altria Group Inc. for oral nicotine products (note 1);
  • 1 new CBD/hemp license to Nuka for beverages across the US;
  • 2 new world-wide beverage licenses to Hill Street Beverages (except Mexico);
  • 2 new Joint Manufacturing Production licenses with Hill Street Beverages for new jointly owned cannabis and CBD brands;
  • 3 new licenses with others for CBD beverages and edible CBD ingredient/products across America.
  • 1 new license for cannabis beverages in California;
  • 1 new multi-state cannabis expansion license with Nuka Enterprises LLC (“Nuka”) for its 1906 Brands for 5 states total, and 2 new product categories

Lexaria now has 9 corporate licensees who are developing innovative beverages, edibles and oral products with their 11 licenses using the Company’s fully patented DehydraTECH absorption technology:


Based on these existing contracts, Lexaria expects to experience unprecedented revenue growth as we estimate many of our clients will commence operations in late 2019 and early 2020. Several of these clients are already planning and preparing for aggressive roll-outs and growth of their product lines. (Note that estimated operations start dates are Lexaria’s own estimates and may or may not reflect actual licensee results.)

Lexaria credits its recent commercial success mainly to its ever-growing body of scientific results evidencing the superior capabilities and power of its patented technologies. Recent 2019 technological advancements are the result of one of the industry’s most focused and productive R&D programs and hold promise for even higher levels of performance from new DehydraTECH innovations with even faster drug delivery into blood plasma and across the blood-brain-barrier.

In one recent animal study, as earlier announced, Lexaria’s latest patent-pending formulations delivered more than 1,900% more CBD into brain tissue than generic industry formulations and achieved peak blood levels more than 800% greater than those of concentration matched controls. In that same animal study, detection of CBD in the bloodstream began in as little as 2 minutes after dosing and peaked in as little as 45 minutes after dosing providing additional support that DehydraTECH enables rapid onset and offset in line with consumer preferences.

Lexaria expects to sign additional new definitive license agreements through the balance of 2019 and beyond as demand for its industry-leading technology continues, and it commends its family of existing licensees and partners that have already joined the Lexaria ecosystem with their exciting products and offerings powered by DehydraTECH.

*Note 1: The license with Altria Ventures Inc is with Lexaria Nicotine LLC, a separate business division of Lexaria Bioscience Corp.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.



Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(250) 765-6424 ext. 202


NetworkNewsWire (NNW)


This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids, nicotine or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

Click here to connect with Lexaria Bioscience Corp. (CSE:LXX, OCT:LXRP) for an Investor Presentation.

Source: www.accesswire.com

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Trading resumes in:

Company: 4Front Ventures Corp.

Keep reading... Show less


  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info: www.bgandg.com/tcmd

Keep reading... Show less

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less